

## ***Embracing the Future of Reproductive Medicine: Ferring Hosts ART FOCUS 2024 in Taiwan, Paving the Way for Personalized Treatment and Innovative Breakthroughs***

- *Ferring hosted 2024 ART FOCUS Pan Asian Symposium in Taipei Taiwan, emphasizing practical applications of scientific discoveries in reproductive medicine that can benefit patients*
- *Reproductive medicine is moving towards personalized treatment, with forums like ART Focus facilitating the sharing of critical clinical experiences that aim to help patients formulate more precise treatment plans*
- *Artificial intelligence (AI) application was discussed by experts to have the potential to make assisted reproductive technology treatment strategies more personalized and precise*
- *Ferring is committed to fostering sustained development and innovative breakthroughs in reproductive medicine, with a vision to inspire new treatment ideas to help people build families.*

**Taipei, Taiwan – 25 June 2024** – This May, Ferring successfully hosted 2024 ART FOCUS Pan Asian Symposium in Taipei Taiwan. The theme of the symposium was “EMBRACING ART BREAKTHROUGHS: CONCEPTS TO CLINICAL APPLICATIONS”, emphasizing the importance of translating scientific discoveries into practical applications that can benefit patients. Reproductive medicine experts from 11 countries around the world were invited to share the real world data, experience, and insights of their clinical treatment and innovative research, attracting nearly 150 international experts and physicians in reproductive medicine from both domestic and abroad to participate.



Given the rapid development of assisted reproductive technology (ART), this year's ART FOCUS agenda covers many key topics, including the impact of Asia's demographic crisis on ART and unmet needs, future fertility preservation technologies, strategies for addressing ovarian aging, the relationship between male age and sperm DNA fragmentation, solutions for diminished ovarian reserve and maximizing ART success for those special subgroup patients. During the conference, speakers from various countries and attending experts shared their prospective studies or retrospective data analysis, exchanged different opinions, debated on those controversial topics, inspired each other on how to optimize ART treatment and improve outcome to help patients build family.

Dave Huang, General Manager of Ferring Taiwan, pointed out that reproductive medicine has entered the era of personalized treatment, which requires reliance on the valuable experience of clinical physicians. Through medical forums like ART FOCUS that facilitate sharing and exchange, more precise treatment plans can be formulated to help more patients.

"Personalized treatment" was one of the key topics discussed at the forum, with reproductive experts from Europe, the Americas, and Asia delving into in-depth discussions on ovarian stimulation protocols for different subgroup patients considering ethnicity and geographical variance. They shared personalized treatment strategies of their respective reproductive institutions and how to optimize them to significantly increase the chances of pregnancy success.

The current hot topic of AI technology applications and its impact on assisted reproduction also sparked lively discussions among the experts present. They explored the future opportunities and possibilities of integrating AI into diagnosis, treatment, and embryology laboratories, including assisting ultrasound image diagnosis, precisely estimating individual initial ovulation stimulation dosages, accurately predicting the best egg retrieval day, etc., potentially helping physicians handle more data to formulate more personalized and precise treatment strategies.

"There has been an upward trend in the age segment and the population of couples suffering from infertility who sought help in assisted reproductive technology in recent years, especially in the wake of delayed marriage and childbearing, which has placed reproductive medicine at the forefront of offering a solution to infertility, as one of the essential medical developments in the world. Important issues include how to provide patients with effective assisted reproductive treatment, help older couples increase their chances of successful pregnancy, and ensure the safety of both mother and child," said Professor Mei-Jou Chen, the Faculty Chair of ART FOCUS 2024 and the President of Taiwan Society for Reproductive Medicine.

"We are striving to help people build families worldwide, where providing patients with high-quality products and services is crucial. By hosting ART FOCUS to promote academic and clinical experience exchange internationally, we hope to inspire new treatment ideas and clinical research directions amongst international experts, as well as to foster the sustainable development and

FERRING Pharmaceuticals Ltd.  
11F, No. 111, Sung Chiang Road, Taipei, Taiwan  
Taipei, Taiwan  
<https://ferring.com.tw/>



## Media Release

innovative breakthroughs in reproductive medicine, thereby benefiting patients. said Eric Breumier, Head of Greater China at Ferring Pharmaceuticals.

- ENDS -

### About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at [ferring.com.tw](https://ferring.com.tw), or connect with us on [LinkedIn](#) · [Instagram](#) · [YouTube](#) · [Facebook](#) and [X \(Twitter\)](#).

### For more information, please contact

#### **Shanniyah Chen**

*Head of Government Affairs, Public Affairs & Comms and Market Access*

+886 2 2515 8277

[shanniyah.chen@ferring.com](mailto:shanniyah.chen@ferring.com)